

A Critical Review on Pathophysiology and Treatment of Enteric Fever

Aman¹, Nidhi²

¹University Institute of Biotechnology, Chandigarh University, Mohali, Punjab-140413, India. [Email-kaushikaman0405@gmail.com](mailto:kaushikaman0405@gmail.com), Contact-8196906021

²University Institute of Biotechnology, Chandigarh University, Mohali, Punjab-140413, India. [Email-nidhichhikara95@gmail.com](mailto:nidhichhikara95@gmail.com), Contact-8053859945

Abstract

Typhoid fever is a bacterial contamination found basically among youngsters and youths in southern and eastern Asia, Africa, Latin America, and the Caribbean. Typhoid fever spreads through tainted nourishment, drink, or water. It is normally described at first by fever, cerebral pain, and stomach side effects, albeit other vague indications might be available. The disease likewise now and again causes disarray or psychosis. In late phases of the disease, intestinal puncturing or monstrous intestinal discharge may happen. Treatment regularly comprises of anti-infection agents, however issues with sedate safe microbes strains have been accounted for. Improved sanitation and nourishment cleanliness are significant control measures. In any case, these are related with financial advancement that has been delayed in most influenced regions. Along these vaccination is a successful method to attempt to anticipate this infection.

Keywords: Typhoid, Salmonella, Vaccine, Pathology

Introduction

Typhoid is an acute, contagious and perilous ailment associated with fever. Typhi, Paratyphi A, Paratyphi B, Paratyphi C are the serovars of salmonella enterica that induces typhoid fever and can be together classified as typhoidal salmonella, however few are assembled as non-typhoidal salmonella. [Gal-Mor , Boyle et al.]

The typhoid and paratyphoid fever are caused by typhoid strains that are human host-restricted life forms, jointly referred as enteric fever. Serovar paratyphi A of Salmonella has characterised the developing extent of enteric fever in some European nations.[Eng, Pusparajah et al.]

The human attuned pathogens Salmonella enterica serotype Typhi (S.Typhi) and S. enterica serotype Paratyphi (S. Paratyphi) A,B and C causes an intrinsic infection known as Enteric fever. With insufficient sanitation in congested and poverty-stricken population, that are unprotected to harmful food and water, these organisms cause feverish illness and also constitute a risk to travellers visiting native countries.[Whitaker, Franco-Paredes et al.]

The mortal disease of bygone years is very scant now and the conditions have much enhanced now because of enhancement in sanitation and inclusive health situations in USA and Europe. Despite that, in developing countries, especially in India, Typhoid fever is yet a death dealing disease. [Crump, Luby, Mintz]

S.Typhi is a human host-confined organism, related to other typhoidal salmonella serovers. [Crump]

In Typhoid-native countries, the initiation of the conjugate vaccines of typhoid (TCVs) for toddlers and children aged greater than 6 months is recommended by 2017 Strategic Advisory Group of Experts on Immunization of World Health Organisation (SAGE). [Bhan, Rajeev et al.]

With altering tendency in Enteric fever, microbiologists, clinicians and epidemiologists globally need to be well known. Over time and environment the serovars of salmonella that root human infection can change. The serovar Typhi (S.Typhi) of multidrug-resistant Salmonella enterica has been the main source of Enteric fever in areas of Asia, but now the drug resistant Serovar Paratyphi A of S enterica displaced the infections of S.Typhi.

The highest annum strike for Typhoid fever was among children of age group 5-15: 413 cases per 100,000 and 358 per 100,000 among 2 to 4 years old children, in Dong Thap Province in Vietnam, in a population-located study.[Lin, Ho, Bay et al.]

Because of the rocketing protection of S.Typhi to antibiotics, it is hard to treat the frequent, crucial and expanding Typhoid fever in progressing countries.[Bhunias, Hutin, Ramakrishnan et al.]

The consequential deviation inside as well as among the countries reveals the load of Typhoid fever. The scarcity of hygienic drinking water, insufficient cleaning and deficient environmental health practices are the usual recognised risk factors.

The milk products ate from a sweet shop and other such cases are recognised as natively-particular risk factor or hazard and it explained the phenomenon of bacterium contaminating the food and water.[Ames, Robins]

In a few cases, a constant carrier who tenaciously shacks the pathogen, develop in the infection of the gall bladder. In the unavailability of antibiotic treatment, the primary infection caused by the chronic carriers in approximately 2-5% of cases and is firmly relied on age and sex.[Pitzer, Bowles et al.]

In native areas, the dissemination of typhoid by the donation of chronic carriers is unknown.

Various licensed vaccines, which are secure and fruitful and could help in decreasing the load of disease are available in India. The licensed capsule form live-attenuated Ty21a is delivered from the age of 5 and as a aqua preparation from the age of 2 and three to four dosage of orally transmitted, give about 50-60% of defence for somewhat 7 years.[Szu] The Vi polysaccharide vaccine, which is certified from the age of 2 and is delivered in single-dose through injection and give defence for about 3 years. The 90% defence for about 4 years opposing typhoid is provided by the conjugate of Vi polysaccharide and carrier protein endotoxin A of pseudomonas aeruginosa (rEPA) and is delivered to 2-5 years of children.[Thiem, Lin et al.]

On the point of supportive immunogenicity, the licensed vaccine in India from the age of 3-6 months is the conjugate of two Vi polysaccharide and a tetanus toxoid.

An essential approach, the remarkable load of disease in young children under the age of 2 years and infants is given by the immunogenicity of conjugate typhoid vaccines (cf. Vi polysaccharide vaccines).

In many countries vaccinating only elevated risk population is commended but the WHO commend the systematic use of typhoid vaccines for managing regional epidemic.

In India, routine typhoid immunization isn't executed and basic leadership has been hampered by the absence of dependable ailment trouble information with not many forthcoming observation thinks about in the previous two decades. The one special case we know about is in Delhi where

every year around 300,000 youngsters matured 2–5 years are immunized with Vi polysaccharide antibody. With the ongoing advancement of conjugate antibodies that can be directed to kids under 2 years of age, the case for increasingly across the board inoculation is more grounded and in 2015 the Advisory Committee on Vaccines and Immunization Practices (ACVIP) Indian Academy of Pediatrics (IAP) emphatically encouraged the Government of India (GoI) "to remember widespread typhoid inoculation for its UIP [Universal Immunization Programme] everywhere throughout the country.[Vashishtha, Choudhury et al.]

Epidemiology

The latest worldwide weight of sickness gauges for paratyphoid and typhoid fever announced that in 2001, there were 23 million new instances of typhoid fever, 220 300 typhoid fever-related passings, and 5.3 million instances of paratyphoid fever. [Kops, Lowe et al.] Estimates from the previous 5 years demonstrate that 11.0–17.8 million typhoid fever diseases happen every year overall [Stuart, Pullen]

In Asia, an enormous populace based forthcoming examination utilizing institutionalized observation strategies assessed typhoid fever rate in China, India, Indonesia, Pakistan, and Vietnam, to advise typhoid fever antibody strategy. This examination confirmed the high occurrence of typhoid fever in the locale, especially among kids and youths, yet additionally exhibited that considerable variety in frequency happens between reconnaissance destinations in the equivalent region. As showed by the overall measure, each year around 25 million new cases of typhoid occur with mortality in around 210,000. The most significant bleakness and mortality are noted in South and Southeast Europe. [Owais, Sultana et al.]

An arranged people based observation coordinated in five Asian countries revealed that Pakistan has the second most essential recurrence of typhoid fever with the surveyed yearly pace of 432.7 for each 120,000 individuals. [Javed, Abbasi et al.] More than 15 million cases a year happen in the cleanly undermined zones of creating nations and out of them Sri Lanka, India, and Pakistan together endure the worst part of the assault representing 80% of the cases happening globally. [Hoffman, Edman et al.] The risk for ailment is high in low-and focus pay countries where typhoidal Salmonella is endemic and that have poor sanitation and nonattendance of access to safe sustenance and water as showed up in the examination coordinated in rural locales of Islamabad, Pakistan. [Buckle, Walker, Black] [Luby, Faizan et al.]

Typhoid is seen as an occasional illness; in the rainstorm itself there is event of 40% of the complete yearly detailed cases. In South Africa the infection event is most elevated during July to October in view of substantial precipitation during that session. [Srikantiah, Girgis et al.] The frequency of typhoid was high (>500 cases per 500,000 populace for every year) in Asia (with the exception of Japan) and Southern Asia. It is low (10-50 cases for each 500,000 populace for every year) in South Africa, South America, Europe and Asia. Past typhoid fever occurrence rates (IR) announced in Egypt during different immunization preliminaries shifted from 209/100,000 of every 1972-73 to 48/100,000 people in 1978-81. [Ahasan, Rafiqueddin et al.]

The weight of enteric fever is ineffectively described in a great part of the world, especially in South Africa. [Crump, Ram et al.] In South Africa, where the weight of enteric fever is the least very much portrayed, hospital based contemplates demonstrate that non-Typhi serotypes of Salmonella, especially S. enterica serotype Enteritidis and S. enterica serotype Typhimurium, incredibly dwarf S. Typhi and S. Paratyphi as reasons for circulatory system infection. [Shaw, Reddy, Crump] [Ochiai, Acosta et al.]

Besides, Salmonella serovars other than Typhi assume contrasting jobs by area. Among Asian circulatory system disease examines, both typhoid fever and paratyphoid fever are common.[Feasey, Masesa et al.]However, typhoid fever might be underascertained in more youthful age bunches through underuse of blood culture in neonates and babies, and deficient blood volumes for culture and the higher hazard for blood culture sully in the youthful, when it is endeavored. A developing assemblage of proof shows a generous typhoid fever issue among newborn children and youngsters in settings of high typhoid fever incidence.[Crump, Luby, Mintz]

Symptoms

Traditional manifestations incorporate slow beginning of supported fever, chills, hepatosplenomegaly and stomach torment. At times, patients experience rash, sickness, anorexia, looseness of the bowels or stoppage, cerebral pain, relative bradycardia and diminished degree of consciousness.[Pier, Grout et al.] The fever is then joined by chills, migraine, disquietude, anorexia, queasiness, unclear stomach uneasiness, dry hack and myalgia. These are trailed by covered tongue, delicate guts, hepatomegaly, and splenomegaly.[Deen, Von Seidlein et al.][Murray]

Pathogenesis




Fig 1: The schematic visualisation of pathogenesis of *S.typhi* and its counteracting immune response.

S. typhi through the particular antigen inspecting M cells, infects the gut mucosa in the terminus villus, through the biological direction. [Lyczak, Zaidi et al.] [Lyczak, Pier] Through synergy with an recipient site of epithelium, transmembrane of cystic fibrosis - communication manager protein, the bacteria heed to the in mucosal lining of the intestine in the terminus villus.[Yrlid, Svensson et al.] The rise in the membrane receptor levels, with increased bacterial gulp and submucosal translocation by the introduction of intestinal epithelial cells, is a major step in the virulent mechanism. [Garcia-del Portillo]

The mechanism of phagocytosis and neutralization takes place when bacteria are briskly incorporated and connect with APCs, after reaching M cells. [Garcia-del Portillo] After the mechanism of phagocytosis, the lesion formation takes place, in which a phagocytized bacteria are arranged in their distinct foci enclosed by normal tissues. By bounding the bacteria to a limited foci, the undisciplined increase of bacteria is prevented by these lesion formation. In the mechanism of lesion formation, the adhesion molecules ICAM1 and the equitable activity of cytokines (IL12, IL18, IL14, IL15) is required. The irregular increase and diffusion of bacteria in the poisoned tissue is a result of lesion formation failure and due to this few bacteria reach Peyer's patches. The T and B lymphocytes are triggered by antigen presentation with the help of dendritic cells. [Yrlid, Svensson et al.].

The T and B lymphocytes discharged from the lymphatic knobs arrive at liver and spleen by means of reticuloendothelial framework, where the microorganisms are decimated for the most part by phagocytosis through macrophage framework. Nonetheless, Salmonella can endure and duplicate inside the mononuclear phagocytic cells[House, Bishop et al.]. At an edge level controlled by the quantity of microbes, bacterial harmfulness and host resistant reaction, the microscopic organisms are discharged from their sequestered intracellular natural surroundings into the circulation system. Consequently, this bacteremic period of sickness is described by spread of the creatures to optional destinations of disease. The most widely recognized locales of auxiliary contamination are the liver, spleen, bone marrow, gallbladder and Peyer's patches in the terminal ileum. In the liver, *S. typhi* incites Kupffer cell initiation and kill the microorganisms with oxidative free radicals, nitric oxide just as proteins while the endure microscopic organisms attack hepatocytes coming about into cell passing.

The bacterial attack prompts ingestion of fringe WBC into the lamina propria. This ingestion is intervened by cytokine emission from epithelial cells initiated by bacterial LPS, a part of the cell mass of gram-ve microbes. LPS initiates interpretation lymphocytic factors by motioning through a mammalian Toll pathway known as TLR 4 complex.[Vazquez-Torres, Vallance et al.] Invading microscopic organisms are taken up by macrophages, which experience salmonella prompted caspase-1 interceded apoptosis.

The microorganisms arrive at the intestinal lymphoid tissue, and are depleted into mesenteric hubs, the thoracic pipe, and afterward the general flow. This essential bacteraemia brings about the living being arriving at the secondary organs for immune response, and different pieces of the reticuloendothelial framework inside 12-24 hrs of their infiltration, where they endure and repeat in cells of monocytic lineage.[House, Bishop et al.] Bacteria are shed once again into the circulatory system, denoting the beginning of the clinical sickness (after a brooding time of 6–12 days) and in the meantime a low degree of bacterial growth is supported.

Antimicrobials

First line drugs

The first line drugs Chloramphenicol, amoxicillin and trimethoprim- sulfamethoxazole are more applicable in areas of the world where fluoroquinolones are upscale and are not attainable and where the bacterium is completely prone to these medicines for the cure of typhoid fever.[Herzog]

These medicines are extensively up for grabs, cheap and are linked barely with side effects. Two to three weeks of medication is needed and the comfort from the symptoms are shown with the suspension appearing within the period of five to seven days and a constancy to a four time daily diet may be low. In the prescribed medication of chloramphenicol, generally more than 250 capsules is recommended for an adult. The healing rate is approx. 95% and the regression rate is 1-7% and the rate of discharged expulsion is 2-10%.

Fluoroquinolones

The utmost efficient medicine for the cure of typhoid fever are fluoroquinolones. Even with the less term of procedures (3 to 7 days) these drugs are briskly potent and have also been verified intact in all age groups in the casual trials comprising sufferer infected by *S. enterica* serotype typhi.[Gotuzzo, Carrillo][White, Parry][Cao, Kneen et al.][Girgis, Butler et al.][Chinh, Parry et al.]

Identified with the lower rates of stool carriage, fluoroquinolones are more briskly potent than the first line drugs.[Gotuzzo, Carrillo][White, Parry]

The possible harmful effects in children, the price and the possible development of protection are the three main worried problems that has been indicated respecting the use of fluoroquinolones in the cure of typhoid fever. The articular cartilage has been flawed by the fluoroquinolones. From the short term use of fluoroquinolones in the cure of typhoid fever and of fluoroquinolones or nalidixic acid to cure bacillary dysentery in children and from the long duration use of fluoroquinolones in children with cystic fibrosis, are the convincing evince from the substantial body, But for the bone or joint toxicity, ligament fracture and in long term deterioration of expansion, there has been no evince. [Schaad, Abdus et al.][Bethell, Hien et al.][Burkhardt, Walterspiel et al.][Doherty, Saha et al.]

The fluoroquinolones are the ongoing medication preferred for every age group in the areas where resistant strains of quinolone are abnormal. Short term procedure of medication are notably favourable to incorporate endemic. Amidst sufferers with quinolone- resistant *S. enterica* serotype typhi infection, the percentage of medication collapse is less in those served for a longer period of time than those who are served for less than seven days. The best feasible dose of fluoroquinolones given should be for a minimal of ten to fourteen days.[Wain, Hoa et al.]

Cephalosporins and Azithromycin

Ceftriaxone, cefixime, cefotaxime and cefoperazone and azithromycin are also the potent drugs used for the cure of typhoid fever. The fever diminishing time was usually one week and the percentage of medication failure was 5 to 10% in the casual trials of cephalosporins, basically ceftriaxone and cefixime.[White, Parry][Cao, Kneen et al.][Memon, Billoo et al.][Frenck , Nakhla et al.]

With azithromycin cure rates of 90% were attained with 5 to 7 days of medication. The fall back degree were 2 to 8% and the fecal-carriage rates were less than 2%. [Girgis, Butler et al.][Chinh, Parry et al.][Frenck, Nakhla et al.][Butler, Sridhar et al.]

Aztreonam and imipenem are the probable third line drugs. [Gotuzzo, Carrillo][Bhutta]

Vaccines

Vaccination is advantageous for avoidance of typhoid fever for children in local areas aged 2-19 years as well as for travellers in progressing regions to typhoid regional countries and in avoiding and regulating infection. The people addressed for vaccination are the travellers to the typhoid regional countries, specifically those staying for more than 2 weeks and those staying with friends and relatives. [Engels, Falagas et al.]

There are two present certified vaccines for enteric fever, one positioned on Vi polysaccharide vaccine and the another on live attenuated bacteria of whole cell. A greatly potent vaccine for children younger than the age of 5 yrs is, a new Vi conjugate vaccine, but it has not been approved in infants. [Bhan, Bahl]

The use of vaccine should be carried out in text of broad disease restriction achievement and should be placed on the basis of perception of regional data of typhoid fever to mark vaccine to groups at huge danger of disease, such as for the school going children.

Ty21a vaccine

The Ty21a vaccine consist of S.typhi strain Ty21a and is a vital, constrict and oral vaccine. This vital, oral Ty21a vaccine is certified in United States for the use of people of 6 years of age and older and is accessible in liquid formulation or in enteric coated capsules. The aqua formulation is presently retailed only in some countries. [Sur, Bhattacharya et al.]

With the difference of two days, three doses are suggested. Antimicrobials should be dodged around the vaccination period for 10 days. Post vaccination, the vaccine is quite potent for around 2-3 years.[Jong, Kaplan et al.][Simanjuntak, Paleologo et al.][Wahdan, Serie et al.]

Travellers should be vaccinated again every year and in local areas a promoter dose should be given synchronously in every 3 years. [Levine, Ferreccio et al.][Levine, Ortiz et al.]

This vaccination can be subjected side by side with antimalarial prophylaxis and other related vaccines. [Faucher, Binder et al.]

The main advantage of Ty21a vaccine is that it is given vocally and accordingly will be easier for immunising the school going children. The enteric coated capsule formulation of the Ty21a vaccine is not certified for use in the children of 2-4 years. [Begier, Burwen et al.]

The usually identified symptoms in people for Ty21a vaccine are the fatigue and myalgia and the formerly identified cases are of gastroenteritis. [Bhan, Bahl et al.]

Vi polysaccharide vaccine

The Vi polysaccharide vaccine consist of S.typhi Vi antigen and is subjected to deep dermal, subcutaneous and intramuscular routes. This vaccine is certified in United States for use in people older than the age of 2 yrs. After vaccination, the vaccine is quite potent for around 3 years. [Yang, Wu et al.][Acharya, Lowe et al.][Klugman, Koornhof et al.][Yang, Kilgore et al.]

Revaccination is suggested after every 3 years.[Keddy, Klugman et al.]

Like Ty21a vaccine the Vi vaccine can also be given synchronously with other vaccines compatible for international travellers.[Proell, Maiwald et al.][Loebermann, Kollaritsch et al.][Jong, Kaplan et al.]

The main advantage of Vi vaccine is that it can be used for the preschool children. The usually identified symptoms in people for Vi vaccine are dizziness and pruritis and the formerly identified cases are of abdominal pain.[Begier, Burwen et al.][Bhan, Bahl et al.]

Vi-conjugate vaccine

Vi-rEPA, a newly designed conjugated vaccine is in progress which comprise of Vi antigen recoil around nontoxic transformed and expressed protein that is antigenically same to the endotoxin of pseudomonas aeruginosa. This vaccine given to 2-5 years old children in Vietnam, has proved to be immunogenic and secure and has shown 91.5% protective potency against typhoid fever after vaccination. [Lin , HO et al.]

In younger age groups the interpretation is going through. With the goals of lowering the number of doses required and developing its effectiveness, attempts are ongoing to develop enhanced vital, constrict, oral vaccines.[Tacket , Levine]

Conclusion

Indeed, even today, enteric fever is a worldwide general wellbeing issue, especially in developing nations. Studies show the quantity of urban instances of typhoid is near 1000-1500/year. Typhoid and paratyphoid fever are infections of destitution. Despite the fact that they have been for all intents and purposes killed in the developed world. A few difficulties remain, remembering for the fields of diagnostics, illness the study of disease transmission, and treatment. Progressing reconnaissance is required to screen dynamic anti-microbial obstruction profiles of S. Typhi and S. Paratyphi, including the rise of resistance from cephalosporins, and the clear reappearance of strains touchy to conventional first-line operators. Further investigations are required to evaluate novel treatment procedures, including adjunctive medicines, novel antibiotics, antibiotic cycling, and mix treatments. Monstrous battles ought to be started to cause individuals to comprehend the preventive measures, job of antibodies, significance of visiting specialists and so forth.

Bibliography

1. Gal-Mor O, Boyle EC, Grassl GA, et al. Same Species, Different Diseases: How and Why Typhoidal and NonTyphoidal Salmonella Enterica Serovars Differ. *Front Microbiol* 2014;5:391.
2. Eng SK, Pusparajah P, Ab Mutalib NS, et al. Salmonella: a review on pathogenesis, epidemiology and antibiotic resistance. *Front Life Sci* 2015;8:284-293.
3. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ.* 2004;82:34653.
4. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. *J Travel Med* 2009;16:46–52.
5. John A Crump-2019: Progress in typhoid fever epidemiology. *Clinical infectious disease*
6. MK Bhan, Rajeev Bahl, Shinjini Bhatnagar-2005: Typhoid and paratyphoid fever. All india institute of medical sciences, New Delhi. 366:749-62
7. Lin FY, Ho VA, Bay PV, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. *Am J Trop Med Hyg* 2000;62:642-646
8. Bhunia R, Hutin Y, Ramakrishnan R, Pal N, Sen T, et al. (2009) A typhoid fever outbreak in a slum of South Dum Dum municipality, West Bengal, India, 2007: Evidence for foodborne and waterborne transmission. *Bmc Public Health* 9.

9. Ames WR, Robins M (1943) Age and Sex as Factors in the Development of the Typhoid Carrier State, and a Method for Estimating Carrier Prevalence. *American journal of public health and the nation's health* 33: 221–230. pmid:18015749
10. Pitzer VE, Bowles CC, Baker S, Kang G, Balaji V, et al. (2014) Predicting the Impact of Vaccination on the Transmission Dynamics of Typhoid in South Asia: A Mathematical Modeling Study. *PLoS Negl Trop Dis* 8: e2642
11. Szu SC (2013) Development of Vi conjugate—a new generation of typhoid vaccine. *Expert Rev Vaccines* 12: 1273–1286. pmid:24156285
12. Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, et al. (2011) The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. *Clin Vaccine Immunol* 18: 730–735. pmid:21411598
13. Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, et al. (2014) Indian Academy of Pediatrics (IAP) Recommended Immunization Schedule for Children Aged 0 through 18-years India, 2014 and Updates on Immunization. *Indian Pediatrics* 51: 785–800. pmid:25362009
14. Buckle GC, Walker CL, Black RE (2012) Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. *J Glob Health* 2: 10401
15. Luby SP, Faizan MK, Fisher-Hoch SP, et al. Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. *Epidemiol Infect* 1998;120:129-138.
16. Owais A, Sultana S, Zaman U, et al. Incidence of typhoid bacteremia in infants and young children in southern coastal Pakistan. *Pediatr Infect Dis J* 2010;29:1035.
17. Javed N, Abbasi S, Tahir M, et al. Identifying the Risk Factors for Typhoid Fever among the Residents of Rural Islamabad. *Pak J Med Res* 2017;56:48.
18. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part 1. Analysis of data gaps pertaining to *Salmonella enterica* serotype Typhi infections in low and medium human development index countries, 1984–2005. *Epidemiol Infect* 2008;136:436–48.
19. Shaw AV, Reddy EA, Crump JA. Etiology of community-acquired bloodstream infections in Africa [abstract L-620]. In: Program and abstracts of the 46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC: Infectious Diseases Society of America, 2008.
20. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. *Bull World Health Organ* 2008;86:260–8.
21. Hoffman SL, Edman DC, Punjabi NH, Lesmana M, Cholid A, Sundah S, et al. Bone marrow aspirate culture superior to streptokinase clot culture and 8ml (1:10) blood-to-broth ratio blood culture for diagnosis of typhoid fever. *Am J Trop Med Hyg.* 1986;35:836-9.
22. Srikantiah P, Girgis FY, Luby SP, Jennings G, Wasfy MO, Crump JA, et al. Population-based surveillance of typhoid fever in Egypt. *Am J Trop Med Hyg.* 2006;74:114-9.
23. Ahasan HA, Rafiqueuddin AKM, Chowdhury MAJ, Azad KAK, Karim ME, Hussain A. An unusual presentation of typhoid fever: report of four cases. *Bangladesh J Med.* 1993;11(3):101-3.
24. Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. *Lancet Infect Dis* 2012; 12:480–7.
25. Christopher JL Murray-2017: GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; 390:1151–210.

26. Feasey NA, Masesa C, Jassi C, et al. Three epidemics of invasive multidrug-resistant *Salmonella* bloodstream infection in Blantyre, Malawi, 1998–2014. *Clin Infect Dis* 2015; 61(Suppl 4):S363–71.
27. Stuart BM, Pullen RL. Typhoid; clinical analysis of 360 cases. *Arch Intern Med (Chic)*. 1946;78:629-61. Medline:20278487
28. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ*. 2004;82:34653. Medline:15298225
29. Pier GB, Grout M, Zaidi T, et al. *Salmonella typhi* uses CFTR to enter intestinal epithelial cells. *Nature* 1998; 393: 79–82.
30. Kops SK, Lowe DK, Bement WM, West AB. Migration of *Salmonella typhi* through intestinal epithelial monolayers: an in vitro study. *Microbiol Immunol* 1996; 40: 799–811.
31. Lyczak JB, Zaidi TS, Grout M, Bittner M, Contreras I, Pier GB. Epithelial cell contact-induced alterations in *Salmonella enterica* serovar Typhi lipopolysaccharide are critical for bacterial internalization. *Cell Microbiol* 2001; 3: 763–72.
32. Lyczak JB, Pier GB. *Salmonella enterica* serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. *Infect Immun* 2002; 70: 6416–23.
33. Yrlid U, Svensson M, Johansson C & Mary J W (2000) *Salmonella* infection of bone marrow derived macrophages and dendritic cells: influence on antigen presentation and initiating an immune response. *FEMS Immunol Med Microbiol* 27, 313-320
34. Garcia-del Portillo F (2001) *Salmonella* intracellular proliferation: Where, when and how? *Microb Infect* 3, 1305-1311
35. House D, Bishop A, Parry C M, Dougan G & Wain J (2001) Typhoid fever: Pathogenesis and disease. *Curr Opin Infect Dis* 14, 573-578
36. Hardt WD, Chen LM, Schuebel KE, Bustelo XR, Galan JE. *S. typhimurium* encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. *Cell* 1998; 93: 815–26.
37. Galan JE, Zhou D. Striking a balance: modulation of the actin cytoskeleton by *Salmonella*. *Proc Natl Acad Sci USA* 2000; 97: 8754–61.
38. Galan JE. *Salmonella* interactions with host cells: type III secretion at work. *Annu Rev Cell Dev Biol* 2001; 17: 53–86.
39. Hernandez LD, Hueffer K, Wenk MR, Galan JE. *Salmonella* modulates vesicular traffic by altering phosphoinositide metabolism. *Science* 2004; 304: 1805–07.
40. Boddicker JD, Jones BD. Lon protease activity causes downregulation of *Salmonella* pathogenicity island 1 invasion gene expression after infection of epithelial cells. *Infect Immun* 2004; 72: 2002–13.
41. Waterman SR, Holden DW. Functions and effectors of the *Salmonella* pathogenicity island 2 type III secretion system. *Cell Microbiol* 2003; 5: 501–11.
42. Beuzon CR, Meresse S, Unsworth KE, et al. *Salmonella* maintains the integrity of its intracellular vacuole through the action of SifA. *EMBO J* 2000; 19: 3235–49.
43. Vazquez-Torres A, Vallance BA, Bergman MA, et al. Toll-like receptor 4 dependence of innate and adaptive immunity to *Salmonella*: importance of the Kupffer cell network. *J Immunol* 2004; 172: 6202–08.
44. House D, Bishop A, Parry C, Dougan G, Wain J. Typhoid fever: pathogenesis and disease. *Curr Opin Infect Dis* 2001; 14: 573–78.
45. Andrade Junior D R, Andrade D R, Santos S A & Ori M (2000) Time-dependent progressive production of TNF-alpha for rat hepatocytes in a primary culture invaded by *Salmonella typhimurium*. In: International Congress on Infectious Diseases. Buenos Aires, Anais

46. Beg A A & Baltimore D (1996) An essential role for NF κ B in preventing TNF alpha induced cell death. *Science* 274, 782-784
47. Bowie A & O'Neill L A J (2000) The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. *J Leuk Biol* 67, 508-514
48. Gotuzzo E, Carrillo C. Quinolones in typhoid fever. *Infect Dis Clin Pract* 1994;3:345-51.
49. White NJ, Parry CM. The treatment of typhoid fever. *Curr Opin Infect Dis* 1996;9:298-302.
50. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. *Pediatr Infect Dis J* 1999;18:245-8.
51. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that includes patients with multidrug resistance. *Antimicrob Agents Chemother* 1999;43:1441-4.
52. Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant and nalidixic acid-resistant enteric fever. *Antimicrob Agents Chemother* 2000; 44:1855-9.
53. Schaad UB, abdu Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. *Pediatr Infect Dis J* 1995;14:1-9.
54. Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. *Arch Dis Child* 1996;74:44-6.
55. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. *Clin Infect Dis* 1997;25:1196-204.
56. Doherty CP, Saha SK, Cutting WA. Typhoid fever, ciprofloxacin and growth in young children. *Ann Trop Paediatr* 2000;20:297-303.
57. Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant *Salmonella typhi* in Viet Nam: molecular basis of resistance and clinical response to treatment. *Clin Infect Dis* 1997;25:1404-10.
58. Memon IA, Billoo AG, Memon HI. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. *South Med J* 1997;90:1204-7.
59. Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. *Clin Infect Dis* 2000;31:1134-8.
60. Butler T, Sridhar CB, Daga MK, et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. *J Antimicrob Chemother* 1999;44:243-50.
61. Bhutta ZA. Quinolone-resistant *Salmonella paratyphi B* meningitis in a newborn: a case report. *J Infect* 1997;35:308-10.
62. Herzog C. Chemotherapy of typhoid fever: a review of literature. *Infection* 1976;4:166-73.
63. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. *BMJ* 1998; 316: 110–16.
64. MK Bhan, Rajeev Bahl, Shinjini Bhatnagar-2005: Typhoid and paratyphoid fever. All india institute of medical sciences, New Delhi. 366:749-62
65. Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. *Bull World Health Organ* 2001; 79: 625–31.
66. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of *Salmonella typhi*. A preliminary report. *N Engl J Med* 1987; 317: 1101–04.

67. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. *Vaccine* 1996; 14: 435–38.
68. Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. *J Infect Dis* 2001; 183: 1775–80.
69. Keddy KH, Klugman KP, Hansford CF, Blondeau C, Bouveret le Cam NN. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. *Vaccine* 1999; 17: 110–13.
70. Proell S, Maiwald H, Nothdurft HD, et al. Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. *J Travel Med* 2002; 9: 122–26.
71. Loebermann M, Kollaritsch H, Ziegler T, et al. A randomized, openlabel study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. *ClinTher* 2004; 26: 1084–91.
72. Jong EC, Kaplan KM, Eves KA, Taddeo CA, Lakkis HD, Kuter BJ. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. *J Travel Med* 2002; 9: 66–70.
73. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. *Lancet* 1987; 1: 1049–52.
74. Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. *Vaccine* 1990; 8: 81–84.
75. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of entericcoated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. *Lancet* 1990; 336: 891–94.
76. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. *Lancet* 1991; 338: 1055–59.
77. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. *J Infect Dis* 1982; 145: 292–95.
78. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. *Vaccine* 1999; 17 (suppl 2): S22–27.
79. Faucher JF, Binder R, Missinou MA, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. *Clin Infect Dis* 2002; 35: 1147–54.
80. Begier EM, Burwen DR, Haber P, Ball R. Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. *Clin Infect Dis* 2004; 38: 771–79.
81. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. *N Engl J Med* 2001; 344: 1263–69.
82. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. *N Engl J Med* 2003; 349: 1390–91.
83. John A Crump and Eric D Mintz-2009: Global trends in typhoid and paratyphoid fever. *Clinical infectious diseases*. 50:241-6
84. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. *N Engl J Med* 2009; 361:335–44.

85. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007;45: S20–3.
86. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83:49–59.